LIPIDS: Treat to Target or with High Intensity (LODESTAR Trial)
'Why we do What we do in Cardiology'15 Jan 2024

LIPIDS: Treat to Target or with High Intensity (LODESTAR Trial)

Key Points from "Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR":

The study compares two strategies for managing LDL cholesterol in coronary artery disease (CAD):

Treat-to-target: aiming for LDL levels between 50-70 mg/dL.

High-intensity statin: prescribing the highest tolerated statin dose regardless of LDL level.

Both strategies are equally effective in preventing major adverse cardiovascular events (MACE) over 3 years:

MACE rate: 8.1% in treat-to-target vs. 8.7% in high-intensity statin (non-inferior).

No significant differences in individual components of MACE (death, MI, stroke, revascularization).

Treat-to-target achieved lower LDL levels initially but the gap closed by year 3.

Safety was similar between groups, but new-onset diabetes trended lower in treat-to-target.

Study limitations:

Open-label design (not blinded).

Limited use of combination therapy (e.g., ezetimibe) with statins.

Implications:

Treat-to-target offers an alternative to the "fire and forget" approach.

May be more patient-centered, allowing dose adjustment based on individual response.

Further research is needed on longer-term outcomes and lower LDL targets.

Additional points:


European guidelines recommend even lower LDL targets (<55 mg/dL) for high-risk patients.

Concerns remain about the potential side effects of high-intensity statin therapy.

Treat-to-target may offer a more cautious and personalized approach.


Link to article: doi:10.1001/jama.2023.2487

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(35)

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left v...

24 Juni 20244min

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF). In this...

22 Juni 20245min

AI in Cardiovascular Medicine: JACC Review

AI in Cardiovascular Medicine: JACC Review

Overview: This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, e...

21 Juni 20246min

2024 ACC Peripheral Artery Disease (PAD) Guidelines

2024 ACC Peripheral Artery Disease (PAD) Guidelines

Collaborative vascular care is emphasized to address health disparities, gaps in medical therapy, structured exercise, and good foot care along with appropriate revascularization to prevent limb loss....

31 Maj 20246min

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Mavacamten: Class 1 recommendation for symptomatic obstructive HCM. Exercise: Now allows for "vigorous" activity; competitive lev...

21 Maj 20249min

DOACs: When direct oral anticoagulants should not be used?

DOACs: When direct oral anticoagulants should not be used?

Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review sup...

29 Jan 20244min

Cath: NPO vs Eating before Heart Cath

Cath: NPO vs Eating before Heart Cath

Background: Traditional practice requires fasting before cardiac catheterization, but there's no evidence to support it. Objective: This study compared a heart-healthy pre-procedure diet with fasting ...

26 Jan 20243min

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Key Points In patients not taking antianginal meds, PCI alleviated some—but not all—symptoms Background: Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptom...

22 Jan 20243min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
rss-vuxna-pa-latsas
bullfika
sexnoveller-deluxe
inga-beiga-morsor
johannes-hansen-podcast
not-fanny-anymore
angestpodden
rss-viktmedicinpodden
sa-in-i-sjalen
tyngre-traningssnack
hacka-livet
rss-autismandan
sova-med-dan-horning
rss-angra-inget-3
rss-hos-psykologen
rss-basta-livet
rss-traningsklubben
psykologsnack